Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?

Mild hypocalcemia was noted during the pivotal clinical registration trials and thus is not too surprising. The reason for the hypocalcemia is not entirely clear but may have to do with blocking sclerostin's stimulatory effect on osteoclasts and/or calcium being "soaked up" by the massive rapid new ...